We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Pooled Saliva Testing for COVID-19 Can Be Cheaper and as Accurate as Individual Nasopharyngeal Diagnostic Tests

By LabMedica International staff writers
Posted on 14 Oct 2021

Testing pooled saliva samples twice weekly for SARS-CoV-2 on a residential college campus yielded a greater than 95% agreement with the gold standard for accuracy—nasopharyngeal diagnostic samples tested singly. More...

The study by researchers at Olivet Nazarene University (Bourbonnais, IL, USA) revealed that at an average of 665 tests per week, the cost, just USD 0.43 per sample, likely remains the least expensive method to date. Using pools of 10 samples, the test provides results in less than eight hours, and is among the most sensitive available, detecting virus at very low viral load, according to the study. This approach enabled successful screening of 43,884 samples, detecting 83% of the semester’s COVID-19 cases. Additionally, the researchers noted that saliva sampling is noninvasive, does not require a transport medium and is stable at room temperature for at least 24 hours.

In the study, students submitted saliva samples once or twice weekly during spring semester, 2021. Saliva samples were collected every weekday before 9am and delivered to the testing lab. Self-collection by students was handled via the honor system, and fewer than 1% of samples were invalid, with 92% submitted on the assigned date. In the study, 36.2% of those tested were asymptomatic, and 48.3 % of participants reported experiencing “very mild” symptoms at the time of testing. This suggests that without the mandatory testing, 84.5% of students might not have gotten tested on their own at the time of screening. Furthermore, only 56% developed flu-like or severe symptoms during their illness. These results raise the possibility that COVID-19 contagion would have swept the college without the testing program.

“Our study demonstrates a significant step forward for achieving rapid test results on a large scale, while preserving supplies and reducing costs,” said study author Daniel R. Sharda, Ph.D. “Our pooled saliva approach puts routine COVID-19 testing within reach for smaller organizations and countries where resources are limited. Future pandemics should use pooled strategies from the very beginning, when tests are otherwise limited.”

Related Links:
Olivet Nazarene University 


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.